Table 2.

Studies evaluating high-dose chemotherapy versus standard dose chemotherapy in relapsed germ cell tumor after first line chemotherapy.

Study	Design	Treatment regimens	N.	Results
Pico et al.8	Phase III	VIP/VeIP × 4 cycles; High-dose CEC	280	CR and PR similar in both arms: 56%; 3-year EFS: 35% vs. 53% (P=0.16); 3-year DFS 55% vs. 57% (P<0.04); 3-year OS similar in both arms: 53%
Lorch et al.9	Phase III	VIP×1 cycle followed by high dose CE×3 cycles (longer course of HDCT); VIP×3 cycles followed by high dose CE×1 cycle (shorter course of HDCT)	216	5-year OS: 49% vs. 39% (P=0.057); 5-year PFS: 47% vs. 45% (P=0.454)
Lorch et al.10	Retrospective analysis	CDCT: Cisplatin-based; HDCT: High dose CE ≥1 cycle with or without additional agents	1984	OR for PFS: 0.44 (95% CI, 0.39 to 0.51), favoring HDCT; OR for OS: 0.65 (95% CI, 0.56 to 0.75), favoring HDCT

VIP, vinblastine, ifosfamide, and cisplatin; VeIP, vinblastine, etoposide and cisplatin; CEC, carboplatin, etoposide and cyclophosphamide; CR, complete response; PR, partial response; EFS, event-free survival; OS, overall survival; PFS, progression-free survival; CDCT, conventional dose chemotherapy; HDCT, high dose chemotherapy; OR, odds ratio